Scientific Presentations for Products in Development

Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links.

To view Encore Presentations, visit our Encore Presentations Page.

First-in-human evaluation of <sup>68</sup>Ga-FAP-2286, a fibroblast activation protein targeted radioligand

Oral Presentation 2022 SNMMI Annual Meeting

<sup>177</sup>Lu-FAP-2286 in patients with advanced or metastatic solid tumors: initial data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)

Oral Presentation 2022 SNMMI Annual Meeting

ATHENA–MONO (GOG-3020/ENGOT-ov45): A Randomized, Double-blind, Phase 3 Trial Evaluating Rucaparib Monotherapy Vs Placebo As Maintenance Treatment Following Response to First-line Platinum-based Chemotherapy In Ovarian Cancer

Oral Presentation 2022 ASCO Annual Meeting

Imaging of Solid Tumors Using <sup>68</sup>Ga-FAP-2286

Poster Presentation 2022 ASCO Annual Meeting

Efficacy and Safety of Rucaparib Maintenance Treatment in Patients From ARIEL3 With Platinum-Sensitive, Recurrent Ovarian Carcinoma Not Associated With Homologous Recombination Deficiency

Poster Presentation 2022 ASCO Annual Meeting

Efficacy and Safety of Lucitanib + Nivolumab in Patients With Advanced Gynecologic Malignancies: Phase 2 Results From the LIO-1 Study (NCT04042116; ENGOT-GYN3/AGO/LIO)

Poster Presentation 2022 ASCO Annual Meeting

Comparative Biodistribution and Radiotherapeutic Efficacy of the Fibroblast Activation Protein (FAP)-Targeting Agents FAP-2286 and FAPI-46

Poster Presentation 2022 AACR Annual Meeting

LuMIERE: A Phase 1/2 Study Investigating Safety, Pharmacokinetics, Dosimetry, and Preliminary Antitumor Activity of <sup>177</sup>Lu-FAP-2286 in Patients With Advanced or Metastatic Solid Tumors

Poster Presentation 2022 AACR Annual Meeting

Nonclinical Evaluation of Rucaparib in Tumors with Mutations in Non-<i>BRCA1/2</i> Homologous Recombination Repair (HRR) genes

Poster Presentation 2022 AACR Annual Meeting

LIO-1: Initial Phase 2 Experience of Lucitanib + Nivolumab in Patients With Metastatic or Recurrent Cervical Cancer (NCT04042116; ENGOT-GYN3/AGO/LIO)

Oral Presentation 2022 SGO Annual Meeting

LuMIERE: A Phase 1/2 Study Investigating Safety, Pharmacokinetics, Dosimetry, and Preliminary Antitumor Activity of <sup>177</sup>Lu-FAP-2286 in Patients With Advanced or Metastatic Solid Tumors – A Trial in Progress

Poster Presentation 2022 SNMMI Mid-Winter and ACNM Annual Meeting

Innovations in Peptide Targeted Radionuclide Therapies (PTRT) to Target Fibroblast Activation Protein (FAP) in Solid Tumors

Virtual Presentation 2021 Targeted Radiopharmaceuticals Summit

Analysis of Patients Who Derived Exceptional Benefit From Rucaparib Maintenance Treatment for High-grade Ovarian Cancer in the Phase 3 ARIEL3 Study

Oral Presentation 2021 ESGO Hybrid Meeting

Pan-Cancer Analysis of Fibroblast Activation Protein Alpha (FAP) Expression to Guide Tumor Selection for the Peptide-Targeted Radionuclide Therapy FAP-2286

Virtual Presentation 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics